Evidence map›Paper›PMID 24699819›Full record

ArticlePLoS pathogens2014

The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER.

Belinda S Hall, Kirsti Hill, Michael McKenna, Joy Ogbechi, Stephen High, Anne E Willis, Rachel E Simmonds

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 3 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 3 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. The dual role of the microbiome in chronic wound management.Cell communication and signaling : CCS · 2026
    Review
  9. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Life (Basel, Switzerland) · 2025
    Review
  14. Article
  15. TheeLife · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Belinda S HallDepartment of Microbial and Cellular Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Kirsti HillThe Babraham Institute, Babraham, Cambridge, United Kingdom.
Michael McKennaFaculty of Life Sciences, University of Manchester, Manchester, United Kingdom.
Joy OgbechiDepartment of Microbial and Cellular Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Stephen HighFaculty of Life Sciences, University of Manchester, Manchester, United Kingdom.
Anne E WillisMRC Toxicology Unit, Leicester, United Kingdom.
Rachel E SimmondsDepartment of Microbial and Cellular Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
University of Surrey · GBUniversity of Manchester · GBBabraham Institute · GBMRC Toxicology Unit · GB

Funding

Medical Research Council MC_UP_A600_1023Wellcome TrustWellcome Trust WT092744
6 · The paper itself

Abstract

Infection with Mycobacterium ulcerans is characterised by tissue necrosis and immunosuppression due to mycolactone, the necessary and sufficient virulence factor for Buruli ulcer disease pathology. Many of its effects are known to involve down-regulation of specific proteins implicated in important cellular processes, such as immune responses and cell adhesion. We have previously shown mycolactone completely blocks the production of LPS-dependent proinflammatory mediators post-transcriptionally. Using polysome profiling we now demonstrate conclusively that mycolactone does not prevent translation of TNF, IL-6 and Cox-2 mRNAs in macrophages. Instead, it inhibits the production of these, along with nearly all other (induced and constitutive) proteins that transit through the ER. This is due to a blockade of protein translocation and subsequent degradation of aberrantly located protein. Several lines of evidence support this transformative explanation of mycolactone function. First, cellular TNF and Cox-2 can be once more detected if the action of the 26S proteasome is inhibited concurrently. Second, restored protein is found in the cytosol, indicating an inability to translocate. Third, in vitro translation assays show mycolactone prevents the translocation of TNF and other proteins into the ER. This is specific as the insertion of tail-anchored proteins into the ER is unaffected showing that the ER remains structurally intact. Fourth, metabolic labelling reveals a near-complete loss of glycosylated and secreted proteins from treated cells, whereas cytosolic proteins are unaffected. Notably, the profound lack of glycosylated and secreted protein production is apparent in a range of different disease-relevant cell types. These studies provide a new mechanism underlying mycolactone's observed pathological activities both in vitro and in vivo. Mycolactone-dependent inhibition of protein translocation into the ER not only explains the deficit of innate cytokines, but also the loss of membrane receptors, adhesion molecules and T-cell cytokines that drive the aetiology of Buruli ulcer.

Indexed as

AnimalsBuruli UlcerCell Adhesion MoleculesCell LineCyclooxygenase 2Endoplasmic ReticulumInflammation MediatorsInterleukin-6LipopolysaccharidesMacrolidesMiceMycobacterium ulceransProtein BiosynthesisProtein TransportTumor Necrosis Factor-alphaCell Adhesion MoleculesCyclooxygenase 2Inflammation MediatorsInterleukin-6LipopolysaccharidesMacrolidesmycolactonePtgs2 protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID24699819
PMCPMC3974873
OpenAlexW2061277860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.